Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19

NCT04355364 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT04355364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04355364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Phase 3
Overall status
Terminated
Start date
April 21, 2020
Completion date
December 20, 2021
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid-19